TY - JOUR
T1 - Design and reporting modifications in industry-sponsored comparative psychopharmacology trials
AU - Safer, Daniel J.
PY - 2002/9/1
Y1 - 2002/9/1
N2 - This review of recently published pharmaceutical industry-sponsored comparative psychotropic drug trials aims to classify apparent design and reporting modifications that favor the sponsor's product. The modifications have been grouped into 13 discrete categories, and representative examples of each are presented. Strong circumstantial evidence suggests that marketing goals led to these adjustments. The consequences of marketing influences on comparative psychopharmacology trials are discussed in terms of conflicts of interest, the integrity of the scientific literature, and costs to consumers, as well as their impact on physician practice.
AB - This review of recently published pharmaceutical industry-sponsored comparative psychotropic drug trials aims to classify apparent design and reporting modifications that favor the sponsor's product. The modifications have been grouped into 13 discrete categories, and representative examples of each are presented. Strong circumstantial evidence suggests that marketing goals led to these adjustments. The consequences of marketing influences on comparative psychopharmacology trials are discussed in terms of conflicts of interest, the integrity of the scientific literature, and costs to consumers, as well as their impact on physician practice.
UR - http://www.scopus.com/inward/record.url?scp=0036742342&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036742342&partnerID=8YFLogxK
U2 - 10.1097/00005053-200209000-00002
DO - 10.1097/00005053-200209000-00002
M3 - Article
C2 - 12357091
AN - SCOPUS:0036742342
VL - 190
SP - 583
EP - 592
JO - Journal of Nervous and Mental Disease
JF - Journal of Nervous and Mental Disease
SN - 0022-3018
IS - 9
ER -